Inogen’s Strong Q3 Performance and Promising Growth Potential Earns Buy Rating
I'm PortAI, I can summarize articles.
Inogen has received a Buy rating from Michael Matson following a strong Q3 performance, with revenue and adjusted EBITDA exceeding expectations. The company saw robust B2B sales, despite lower DTC sales, and launched the Voxi 5 stationary oxygen concentrator. Inogen has achieved mid-single-digit revenue growth and anticipates 9-12% growth in Q4 2025, indicating a positive outlook and potential for further improvement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments